levodopa has been researched along with Cardiovascular Diseases in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (38.10) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Aridon, P; Arnao, V; Buttà, C; Cinturino, A; D'Amelio, M; Maida, C; Mastrilli, S; Tuttolomondo, A | 1 |
| Calia, K; Graham, DJ; Hsueh, YH; Kelman, JA; Levenson, M; Macurdy, TE; Pinheiro, SP; Shih, D; Williams, JR; Worrall, C | 1 |
| Kulisevsky, J; Pagonabarraga, J | 1 |
| Barichella, M; Canesi, M; Cassani, E; Cavanna, F; Cazzola, R; Cereda, E; Cestaro, B; Iorio, L; Natuzzi, F; Pezzoli, G; Pinelli, G; Pusani, C | 1 |
| Bloem, BR; Munneke, M; Petzinger, GM; Speelman, AD; van de Warrenburg, BP; van Nimwegen, M | 1 |
| Krzyściak, W | 1 |
| Ahn Jo, S; Han, C; Jo, I; Lee, JM; Park, KW; Park, MH; Seo, WK | 1 |
| Morris, JG | 1 |
| Wick, MM | 1 |
| Palmiter, RD; Quaife, CJ; Zhou, QY | 1 |
| Jellinger, KA | 1 |
| Myllylä, VV; Sotaniemi, K; Suominen, K; Tolonen, U; Turkka, J | 1 |
| Boonkongchuen, P; Churchyard, A; Lees, AJ; Mathias, CJ | 1 |
| Fowler, B; Hauptmann, B; Kuhn, W; Müller, T; Woitalla, D | 1 |
| Bianchine, JR; Shaw, GM | 1 |
| Piccirilli, M; Quartesan, R | 1 |
| Korczyn, A; Salganik, I | 1 |
| Nishizawa, T | 1 |
| Fischer, GJ; Quandt, J; Sommer, H | 1 |
| Ferrari, E | 1 |
| Il'inskiĭ, IA; Safronov, VA; Vasin, NIa | 1 |
4 review(s) available for levodopa and Cardiovascular Diseases
| Article | Year |
|---|---|
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indans; Indoles; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Parkinson Disease; Serotonin Syndrome; Treatment Outcome | 2014 |
How might physical activity benefit patients with Parkinson disease?
Topics: Antiparkinson Agents; Cardiovascular Diseases; Cognition; Constipation; Depressive Disorder; Dopamine; Humans; Levodopa; Motor Activity; Muscle Fatigue; Osteoporosis; Parkinson Disease; Psychomotor Performance; Quality of Life; Sedentary Behavior; Sleep Wake Disorders | 2011 |
Activity of selected aromatic amino acids in biological systems.
Topics: Biomarkers; Cardiovascular Diseases; Enzyme Activation; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Levodopa; Melanins; Monophenol Monooxygenase; Nervous System Diseases; Oxidative Stress; Renal Insufficiency, Chronic; Serotonin; Tryptophan; Tyrosine | 2011 |
Clinical pharmacokinetics of levodopa in parkinson's disease.
Topics: Carboxy-Lyases; Cardiovascular Diseases; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gastric Mucosa; Gastrointestinal Diseases; Homovanillic Acid; Humans; Intestinal Absorption; Kinetics; Levodopa; Mental Disorders; Parkinson Disease; Pyridoxine; Stimulation, Chemical; Time Factors | 1976 |
3 trial(s) available for levodopa and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cardiovascular Diseases; Catechols; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease; Risk; Treatment Outcome | 2013 |
Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.
Topics: Analysis of Variance; Autonomic Nervous System Diseases; Blood Pressure; Cardiovascular Diseases; Electrocardiography; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Prospective Studies; Reflex; Selegiline; Tilt-Table Test | 1997 |
Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Movement Disorders; Parkinson Disease; Selegiline | 1997 |
14 other study(ies) available for levodopa and Cardiovascular Diseases
| Article | Year |
|---|---|
Impaired circadian heart rate variability in Parkinson's disease: a time-domain analysis in ambulatory setting.
Topics: Aged; Antiparkinson Agents; Cardiovascular Diseases; Circadian Rhythm; Heart Rate; Humans; Levodopa; Middle Aged; Parkinson Disease; Pilot Projects; Primary Dysautonomias | 2020 |
Endothelial progenitor cells: Cardiovascular protection in Parkinson's disease?
Topics: Aged; Cardiovascular Diseases; Endothelial Progenitor Cells; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2015 |
Carotid intima-media thickness in Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Cardiovascular Diseases; Carotid Arteries; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Risk Assessment; Ultrasonography | 2007 |
The drug treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nausea; Parasympatholytics; Parkinson Disease | 1984 |
The chemotherapy of malignant melanoma.
Topics: Carbidopa; Cardiovascular Diseases; Dopamine; Drug Evaluation; Humans; Levodopa; Melanoma; Mitotic Index; Skin Neoplasms | 1983 |
Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development.
Topics: Alleles; Animals; Base Sequence; Cardiovascular Diseases; Catecholamines; Cell Line; DNA; Embryonic and Fetal Development; Female; Levodopa; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Molecular Sequence Data; Mutagenesis; Pregnancy; Tyrosine 3-Monooxygenase | 1995 |
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.
Topics: Antiparkinson Agents; Cardiovascular Diseases; Cause of Death; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline | 1996 |
Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Cardiovascular Diseases; Dopa Decarboxylase; Down-Regulation; Drug Interactions; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Methionine; Middle Aged; Parkinson Disease; S-Adenosylmethionine; Up-Regulation | 2001 |
[Review of problems in the treatment of the parkinsonian syndrome with L-dopa].
Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Hypertension; Hypotension, Orthostatic; Levodopa; Movement Disorders; Parkinson Disease, Secondary; Psychoses, Substance-Induced | 1976 |
Risk factors for dementia in Parkinson's disease.
Topics: Aged; Cardiovascular Diseases; Dementia; Diabetes Complications; Female; Humans; Levodopa; Male; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Risk Factors; Smoking | 1990 |
[Secondary hyperuricemia].
Topics: Cardiovascular Diseases; Diuretics; Endocrine System Diseases; Ethanol; Fructose; Gout; Hematologic Diseases; Humans; Levodopa; Nutritional Physiological Phenomena; Proteins; Purines; Uric Acid; Urologic Diseases | 1985 |
[The problem of side effects after a treatment with L-dopa in the Parkinson's syndrome: clinical and animal studies (author's transl)].
Topics: Adult; Aged; Brain; Cardiovascular Diseases; Dopamine; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Pain; Paresthesia; Parkinson Disease, Secondary; Psychoses, Substance-Induced | 1974 |
[Problems in the administration of L-DOPA (author's transl)].
Topics: Cardiovascular Diseases; Drug Eruptions; Gastrointestinal Diseases; Humans; Levodopa; Mental Disorders; Movement Disorders; Parkinson Disease; Urologic Diseases; Vision Disorders | 1974 |
[L-dopa therapy for Parkinsonism and its relationship to surgical methods of treatments].
Topics: Cardiovascular Diseases; Dyspepsia; Fear; Hallucinations; Humans; Hyperkinesis; Levodopa; Mental Disorders; Nausea; Parkinson Disease; Postoperative Care; Preoperative Care; Vomiting | 1974 |